Page 97 - Sitomegalovirüs Tanı, Tedavi Uzlaşı Raporu

Transplant. 2013;13(4):93-106.
50. Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin
Microbiol Rev. 2010;23:689-712.
51. Macesic N, Langsford D, Nicholls K, et al. Adoptive T cell immunotherapy for
treatment of ganciclovir-resistant cytomegalovirus disease in a renal transplant
recipient. Am J Transplant. 2015;15:827-832.
52. Papadopoulou A, Gerdemann U, Katari UL, et al. Activity of broad-spectrum T cells
as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl
Med. 2014;6(242):242ra83.
53. Brestrich G, Zwinger S, Fischer A,et al. Adoptive T-cell therapy of a lung transplanted
patient with severe CMV disease and resistance to antiviral therapy. Am J Transplant.
2009;9(7):1679-84.
54. Nashan B, Gaston R, Emery V, et al. Review of cytomegalovirus infection findings
with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in
de novo renal transplant recipients. Transplantation. 2012;93(11):1075-1085.
55. Avery RK, Mossad SB, Poggio E, et al. Utility of leflunomide in the treatment of
complex cytomegalovirus syndromes. Transplantation. 2010;90(4):419-426.
56. Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, Haider S,
Ullmann AJ, Katayama Y, Brown J, Mullane KM, Boeckh M, Blumberg EA, Einsele H,
Snydman DR, Kanda Y, DiNubile MJ, Teal VL, Wan H, Murata Y, Kartsonis NA,
Leavitt RY, Badshah C. Letermovir Prophylaxis for Cytomegalovirus in
Hematopoietic-Cell Transplantation.N Engl J Med. 2017;377(25):2433-2444.
57. Winston DJ, Saliba F, Blumberg E et al. Efficacy and safety of maribavir dosed at 100
mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant
recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant.
2012;12(11):3021-30.
58. George B, Pati N, Gilroy N, et al. Pre-transplant cytomegalovirus (CMV) serostatus
remains the most important determinant of CMV reactivation after allogeneic
hematopoietic stem cell transplantation in the era of surveillance and preemptive
therapy. Transpl Infect Dis. 2010;12(4):322-329.
59. Rowe RG, Guo D, Lee M, et al. Cytomegalovirus infection in pediatric hematopoietic
stem cell transplantation: risk factors for primary infection and cases of recurrent and
late infection at a single center. Biol Blood Marrow Transplant. 2016;22(7):1275-1283.
60. Massoud R, Assi R, Fares E, Haffar B, Charafeddine M, Kreidieh N, Mahfouz R, Kanj
SS, El Zakhem A, Kharfan-Dabaja M, Bazarbachi A, El Cheikh J. Cytomegalovirus
reactivation in lymphoma and myeloma patients undergoing autologous peripheral
blood stem cell transplantation. J Clin Virol. 2017;95:36-41.
61. Schmidt-Hieber M, Labopin M, Beelen D, Volin L, Ehninger G, Finke J, Socié G,
Schwerdtfeger R, Kröger N, Ganser A, Niederwieser D, Polge E, Blau IW, Mohty M.
CMV serostatus still has an important prognostic impact in de novo acute leukemia
patients after allogeneic stem cell transplantation: a report from the Acute Leukemia
Working Party of EBMT. Blood. 2013;122(19):3359-64.
62. Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, Green JS, Saad
A, Antin JH, Savani BN, Lazarus HM, Seftel M, Saber W, Marks D, Aljurf M, Norkin M,
Wingard JR, Lindemans CA, Boeckh M, Riches ML, Auletta JJ. Early cytomegalovirus
reactivation remains associated with increased transplant-related mortality in the
current era: a CIBMTR analysis. Blood. 2016;127(20):2427-38.

94